GPRC5D Targeted Therapies Market Outlook 2026–2030 Highlighting Key Trends and Drivers
The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Change Between 2026 And 2030?
The market for g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies has seen substantial growth in recent times. It is anticipated to increase from $0.59 billion in 2025 to $0.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 32.7%. This past growth is attributable to advancements in targeted cancer therapy research, a rising incidence of multiple myeloma, the expansion of monoclonal antibody development initiatives, better clinical trial infrastructure, and increased investment in oncology drug discovery.
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market size is anticipated to experience substantial growth in the coming years. It is projected to reach $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 32.9%. This expansion during the forecast period is propelled by factors such as an increase in regulatory approvals for targeted biologics, a growing demand for personalized cancer treatments, the broadening of next-generation immunotherapy platforms, rising investments in precision medicine ecosystems, and the wider adoption of biomarker-based therapy selection. Prominent trends observed for this period include the increased development of bispecific antibody therapies, a heightened focus on gprc5d biomarker-driven patient selection, the expanding use of CAR-T cell platforms, the enlargement of precision oncology clinical pipelines, and improved integration of companion diagnostics.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33116&type=smp
What Core Drivers Are Transforming The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?
An increase in myeloma prevalence is projected to boost the expansion of the GPRC5D-targeted therapies market. Myeloma, a form of cancer affecting plasma cells within the bone marrow, interferes with typical blood cell formation and may lead to issues such as bone damage, anemia, and kidney dysfunction. The growing incidence of myeloma is partly attributable to demographic aging, since the likelihood of developing plasma cell disorders escalates with advancing age due to the gradual accumulation of genetic mutations. GPRC5D-targeted therapies offer a treatment approach for myeloma by attaching to the GPRC5D protein present on cancerous plasma cells. This mechanism guides the immune system, particularly T cells, to specifically eliminate these malignant cells while largely preserving healthy ones. For example, the American Cancer Society, a US-based professional organization, projected in January 2026 that in 2026, the United States is likely to observe about 36,000 new cases of multiple myeloma, comprising 20,150 cases in men and 15,850 cases in women. Additionally, approximately 10,850 deaths are expected, with 5,780 men and 5,070 women affected. Consequently, the increasing prevalence of myeloma is fueling the growth of the GPRC5D-targeted therapies market.
Which Segment Divisions Form The Structure Of The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Chimeric Antigen Receptor (CAR-T) Cell Therapies; Other Therapy Types
2) By Indication: Multiple Myeloma; Solid Tumors; Other Indications
3) By Technology: Precision Medicine Approaches; Molecular Targeted Therapy; Cancer Immunotherapy Platforms; Biopharmaceutical Drug Delivery Systems
4) By Route Of Administration: Intravenous; Subcutaneous; Other Routes Of Administration
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
2) By Bispecific Antibodies: Dual Targeting Bispecific Antibodies; Cross Linking Bispecific Antibodies; Immune Cell Engaging Bispecific Antibodies; Cytotoxic Bispecific Antibodies
3) By Chimeric Antigen Receptor (CAR-T) Cell Therapies: Autologous Car T Cell Therapies; Allogeneic Car T Cell Therapies; Next Generation Car T Cell Therapies; Gene Edited Car T Cell Therapies
4) By Other Therapy Types: Targeted Small Molecule Drugs; Receptor Specific Inhibitors; Injectable Biologics; Oral Targeted Therapeutics
What Trends Are Influencing The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Outlook?
Leading firms within the GPRC5D targeted therapies market are concentrating on creating novel therapies, specifically bispecific T cell engagers, aimed at strengthening the immune system’s ability to target cancer cells and boosting treatment effectiveness. A bispecific T-cell engager (BiTE) represents an immunotherapy molecule engineered to forge a direct link between T-cells and cancer cells, simultaneously binding to both, thereby stimulating T-cells to eliminate the designated cancer cells. As an illustration, in August 2023, Johnson & Johnson, a healthcare firm based in the US, secured approval from the European Commission for TALVEY (talquetamab), Janssen’s bispecific antibody therapy that targets GPRC5D, intended for treating relapsed and refractory multiple myeloma (RRMM) in patients who have undergone at least three prior therapies. This particular therapy stands as a first-in-class bispecific T-cell engager, designed to target GPRC5D found on multiple myeloma cells and CD3 on T cells, for addressing relapsed/refractory multiple myeloma in patients extensively pretreated. Its primary objective is to deliver enduring responses (with an ORR >70% observed in trials) following at least four prior therapies, offering benefits such as subcutaneous administration, maintained improvements in quality of life, and continued effectiveness even after bispecific or CAR-T treatments, thereby addressing a critical unmet requirement in advanced-stage disease.
Which Organizations Are Operating Within The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?
Major companies operating in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market are Johnson And Johnson, F. Hoffmann-La Roche AG., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Bristol Myers Squibb Company, Genmab A/S, Genentech Inc., Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., ShanghAI Yake Biotechnology Co. Ltd., Guangzhou Bio-gene Technology Co. Ltd.
Access The Complete G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report:
Which Region Accounts For The Highest Share Of The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?
North America was the largest region in the GPRC5D targeted therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Customized G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report for Deeper Competitive Insights
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
